Shockwave Medical became the first entrant in the IVL space with the European launch of its IVL system for treating peripheral arterial disease (PAD) in 2017, following its receipt of CE mark in 2015. In 2016, the company became the first with an IVL system for PAD treatment to receive US Food and Drug Administration (FDA) approval, launching its first IVL catheter in the US in 2021.
Since its first product launches, Shockwave was acquired by Johnson and Johnson (J&J) in a $13.1bn deal in June 2024.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With its first-to-market advantage, Shockwave already has a significant user base. According to Dr Nick West, chief medical officer at the company, many physicians now report that Shockwave’s IVL catheters have become their standard of care (SoC) approach to treating calcified plaques.
Medical Device Network spoke with West to learn more about the company’s views on the current state of the IVL market, and how it plans to retain its leading position as the field attracts ongoing interest from some of the largest players in the medtech industry.
Listen to the full episode below:
